https://www.selleckchem.com/pr....oducts/epz015666.htm
The median TTP was 2.96 months (95% CI 1.61 to 4.31). Median OS was 10.9 months (95% CI 3.99 to 17.8) and the 1 year, 2 year and 3 year survival rates were 42.4%, 32.3% and 21.6%, respectively. The ORR was 16.7% in primary resistance group and 15.4% in acquired resistance group (p=1.0. All responders were of CP A and Albumin-Bilirubin (ALBI) Grade 1 or 2. CP and ALBI Grades were significantly associated with OS (p=0.006 and p0.001, respectively). Overall, 52% of patients experienced TRAEs and 12% experienced Grade 3 or above TRA
Like
Comment
Share
